Life expectancy -

May 12 – International CFS Day: A Time for Awareness, Empathy, and New Perspectives

International CFS Day is held every year on May 12—an important occasion to raise awareness ofChronic Fatigue Syndrome (CFS) also known as ME/CFS (Myalgic Encephalomyelitis / Chronic Fatigue Syndrome) . Despite its significant impact on the lives of those affected, CFS remains a widely underestimated and often misunderstood condition. The day of action is therefore dedicated to education, solidarity, and scientific discourse.

What is ME/CFS?

ME/CFS is a complex, neurological multisystem disorder that affects the nervous system, the immune system, and energy metabolism. It is characterized by profound, long-lasting exhaustion, also known as fatigue.

According to estimates, approximately 17 millionpeople worldwide1 are affected, including children and adolescents. For many of those affected, the condition leads to significant physical, occupational, and social limitations.

Symptoms

The most common symptoms include:

  • Fatigue – persistent, pathological exhaustion and the primary symptom of CFS/ME
  • Post-Exertional Malaise (PEM) – a significant deterioration in condition following minimal exertion
  • Problems with concentration and memory (“brain fog”)
  • Sleep problems despite feeling very tired
  • Muscle aches, headaches, flu-like symptoms
  • Circulatory problems, sensitivity to light and noise

Fatigue – more than just tiredness

Fatigue is a term often translated as “tiredness”—but that falls far short of the mark, as fatigue differs fundamentally from normal tiredness. In medical contexts, fatigue describes a state of deep, debilitating exhaustion that cannot be alleviated by sleep, rest, or recuperation.

In CFS, fatigue is not merely a symptom, but the defining characteristic. Unlike “normal” tiredness, it is profound and long-lasting— affecting the body, mind, and emotions. Furthermore, it is out of proportion to any prior exertion and can occur in episodes or be constant.

Those affected often describe fatigue as a feeling as though their body has “shut down,” accompanied by muscle weakness, difficulty concentrating, and a sense of inner emptiness. Even simple tasks like brushing teeth, climbing stairs, or having a brief conversation can feel overwhelming. Many also experience mental exhaustion, also known as “brain fog,” which impairs thinking, memory, and speech.

Fatigue is not limited to ME/CFS; it also occurs in other chronic conditions such as multiple sclerosis, cancer, rheumatic diseases, and long COVID. Nevertheless, it often goes unrecognized because it cannot be objectively measured—and because it is not outwardly visible.

Post-Exertional Malaise (PEM)

In addition to fatigue, post-exertional malaise (PEM) is a particularly defining feature of ME/CFS. PEM is characterized by a dramatic deterioration in one’s condition following even minimal physical or mental exertion. These “crashes” can last for days or weeks and often occur with a delay, making the condition difficult to plan for and highly stressful.


Research and New Approaches

Research on ME/CFS is still in its early stages—for a long time, the condition was underestimated or misclassified. The causes of ME/CFS are still not fully understood. It is only in recent years that the biological causes have come more into focus, partly due to the rise in cases of Long COVID with similar symptoms.

Current studies are examining, among other things, disturbances in energy metabolism, dysregulation of the immune system, and impairments of the nervous system. The goal is to identify reliable biomarkers and, in the long term, develop targeted therapies.

Despite many unanswered questions, international research activity is on the rise—and with it, the hope for medical progress and better care for those affected.

A Day of Solidarity – and a Call to Action

Despite the severity of the condition, ME/CFS often goes undiagnosed or is misdiagnosed—with far-reaching consequences for those affected. Many experience not only physical suffering but also social isolation, bureaucratic hurdles, and a lack of medical support. International CFS Day therefore sends a clear message:

  • For more information on symptoms and the course of the disease
  • For empathy toward those who are ill
  • For research that seeks to identify biological causes
  • For societal recognition of a serious illness

CFS is real, complex, and life-altering. This day of action reminds us that raising awareness can improve lives—through greater understanding, better medical care, and targeted research. Let’s not leave those affected to face this alone—neither their illness nor their struggle for recognition.

Sources and further information

  1. German Society for ME/CFS
    Information platform with scientifically based content on symptoms, diagnosis, research findings, and the social situation.
    https://www.mecfs.de
  2. Austrian Society for ME/CFS (ÖG ME/CFS)
    Professional association for Austria providing current statistics, medical recommendations, and public awareness campaigns.
    https://www.oegmecfs.at
  3. National Academy of Medicine (USA)
    Groundbreaking report: Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness (2015)
    https://nap.nationalacademies.org/catalog/19012/
  4. Centers for Disease Control and Prevention (CDC, USA)
    Medical definitions, research approaches, and patient information on ME/CFS.
    https://www.cdc.gov/me-cfs/
  5. World Health Organization (WHO)
    ME/CFS has been classified as a neurological disorder under ICD-10 G93.3 since 1969.
    https://icd.who.int/browse10/2019/en#/G93.3
  6. Charité Fatigue Center, Berlin
    University research institute specializing in fatigue and ME/CFS.
    https://cfc.charite.de
  7. Euromene (European ME/CFS Research Network)
    European research network for epidemiological surveys and the coordination of studies on ME/CFS.
    https://www.euromene.eu

 

 

Leave a comment

Please note that comments must be approved before they are posted

This site is protected by hCaptcha, and hCaptcha's Privacy Policy and Terms of Service apply.

Back to "Everything About Nutrition, Exercise, and NADH"

FAQs

The term “weight-loss injection” refers to various
prescription medications that are used under certain
medical conditions to treat overweight and obesity
. Well-known active ingredients include semaglutide and tirzepatide.
Among other things, they influence hunger and feelings of fullness and can thereby
reduce energy intake.

GLP-1 stands for glucagon-like peptide-1 and is a naturally occurring hormone in the body
. Among other things, it plays a role in regulating
appetite, satiety, and glucose metabolism. GLP-1-based medications mimic
the effects of this hormone and specifically activate the GLP-1 receptor.

The term “GLP-1 dietary supplement” is not medically defined at
. It generally refers to products marketed as “GLP-1 Support”
or “GLP-1 Booster,” which may contain, for example, dietary fiber,
protein, prebiotics, or plant compounds such as berberine.

What matters most here is the specific ingredient and its scientifically studied effects (
)—not just the name of the product (
).

Dietary supplements and GLP-1 medications
have different mechanisms of action. Medications such as semaglutide or tirzepatide
specifically target certain hormonal signaling pathways. Certain nutrients
and plant compounds, on the other hand, can support other physiological processes,
such as satiety, digestion, or metabolism.

They should therefore not be equated with the pharmacological effects
of GLP-1 medications.

Of particular interest are ingredients associated with satiety,
digestion, or the gut microbiota. These include , for example ,
soluble and fermentable dietary fibers, prebiotics, and
certain plant compounds.

Among other things, dietary fiber can influence digestion
and, through fermentation in the gut, contribute to the formation of short-chain
fatty acids. These, in turn, can influence signaling pathways associated with
the release of gut hormones such as GLP-1.

However, the effect depends heavily on the specific ingredient,
the dosage, and the individual's situation.

Dietary fiber can contribute to a balanced diet
and, among other things, promote satiety and aid digestion.
Soluble and fermentable dietary fibers are particularly noteworthy in this context
.

Good natural sources include vegetables,
legumes, whole grains, fruits, nuts, and seeds. Certain
dietary fibers, such as psyllium or inulin, are also used as dietary supplements.

Protein provides important amino acids for the maintenance and
growth of muscle tissue. An adequate protein intake is therefore particularly important
during significant weight loss.

When combined with regular strength training,
a high-protein diet can help preserve lean body mass as much as possible during
weight loss.

In general, there is no comprehensive list of
foods that are strictly prohibited during GLP-1 therapy.
However, appetite, feelings of fullness, and, in some cases,
tolerance to certain foods may change.

When people eat less overall, the nutritional quality of their diet
 becomes more important. Protein-rich foods, vegetables, fruits,
whole grains, legumes, and other nutrient-dense foods can
serve as an important foundation.

Studies show that weight regain can occur after discontinuing GLP-1-based
medications. In the extension
of the STEP-1 study, participants regained, on average, a significant portion of the weight they had previously
lost within one year of
discontinuing semaglutide.

This underscores the importance of long-term, sustainable
dietary and physical activity habits, even during medication-based
therapy.

GLP-1 therapy does not require a specific diet
. However, since feelings of hunger and fullness change and
people sometimes eat less, it may be helpful to focus
particularly on nutrient density, protein, fiber, and a
varied selection of foods.

Regular exercise, especially strength training, can also be a useful addition to
.

No. GLP-1 dietary supplements and
GLP-1 medications must always be distinguished from one another.

Drugs such as semaglutide and tirzepatide were specifically developed
to activate certain hormonal signaling pathways and have been studied as medications in
clinical trials. Dietary supplements
, on the other hand, contain nutrients or other bioactive substances that can support natural
physiological processes.

The term “GLP-1” on a dietary supplement
therefore does not mean that the product has the same effect as a GLP-1 medication
.